Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9236
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGibbs, Pen
dc.contributor.authorHutchins, A Men
dc.contributor.authorDorian, K Ten
dc.contributor.authorVaughan, Hilary Aen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorSilvapulle, Men
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-15T22:15:08Z
dc.date.available2015-05-15T22:15:08Z
dc.date.issued2000-06-01en
dc.identifier.citationMelanoma Research; 10(3): 259-64en
dc.identifier.govdoc10890380en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9236en
dc.description.abstractMAGE proteins have been identified as potential specific targets for cancer vaccination. Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this malignancy. These are of relevance particularly for MAGE-6 as recent studies have identified CTL activity against several epitopes. We have studied MAGE-1, -2, -3, -4, -6 and -12 gene expression using reverse transcription-polymerase chain reaction in 47 melanoma samples and 11 melanoma cell lines established from these tumours. The tumour samples expressed MAGE-12 (74%) and MAGE-6 (64%) mRNA at much higher frequencies than the other MAGE genes. MAGE-12 and MAGE-6 were expressed at the highest frequencies, relative to the other MAGE antigens, in early stage lesions. The frequency of expression of all the MAGE genes was found to be higher in samples from metastatic deposits compared to those from locoregional disease. The cell lines all expressed the same or more MAGE antigens than the tumours from which they were derived. In only one cell line was expression of a MAGE antigen lost. Certain recurring patterns of MAGE expression were observed in the tumour samples. MAGE-6 and/or -12 expression were detected in all of those 26 tumour samples that were positive for one or more of MAGE-1, -2, -3 and -4. Twenty of these 26 samples expressed both antigens. These findings suggest that protocols targeting MAGE-12 and -6 would permit many more patients to be included into clinical cancer vaccination trials.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAntigens, Neoplasm.biosynthesis.geneticsen
dc.subject.otherDNA Primers.chemistryen
dc.subject.otherGene Expressionen
dc.subject.otherHumansen
dc.subject.otherMelanoma.genetics.metabolism.pathologyen
dc.subject.otherMiddle Ageden
dc.subject.otherNeoplasm Proteins.biosynthesis.geneticsen
dc.subject.otherRNA, Messenger.biosynthesisen
dc.subject.otherReverse Transcriptase Polymerase Chain Reactionen
dc.subject.otherSequence Analysis, DNAen
dc.subject.otherSkin Neoplasms.genetics.metabolism.pathologyen
dc.subject.otherTumor Cells, Cultureden
dc.titleMAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleMelanoma researchen
dc.identifier.affiliationLudwig Institute for Cancer Research and the Medical Oncology Department of the Austin and Repatriation Medical Centre, Heidelberg, Australiaen
dc.description.pages259-64en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/10890380en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.